ସୋଟ୍ରୋଭିମାବ

ସୋଟ୍ରୋଭିମାବ
	A vial of sotrovimab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Spike protein of SARS-CoV-2
Clinical data
Trade names	Xevudy
Synonyms	VIR-7831, GSK4182136
AHFS/Drugs.com	monograph
data	EU EMA: yes; US DailyMed: Sotrovimab;
Pregnancy; category	AU: B2 ; ;
Routes of; administration	Intravenous
Legal status
Legal status	AU: S4 (Prescription only) ; US: Unapproved; Emergency Use Authorization ;

ସୋଟ୍ରୋଭିମାବ ହେଉଛି ଏକ ଔଷଧ, ବିକ୍ରୟ ନାମ ଜେଭୁଡି, ଯାହାକି କୋଭିଡ-୧୯ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ, ଯେଉଁମାନଙ୍କ ପାଇଁ ସପ୍ଲିମେଣ୍ଟାରୀ ଅମ୍ଳଜାନର ଆବଶ୍ୟକତା ନାହିଁ କିନ୍ତୁ ଗୁରୁତର ରୋଗ ହେବାର ଆଶଙ୍କା ଅଧିକ ଥାଏ ।^[୧] ଏହି ଗୋଷ୍ଠୀରେ ଏହା ଡାକ୍ତରଖାନାର ଆବଶ୍ୟକତା ହ୍ରାସ କଲା | ^[୬] ଏହା ଓମିକ୍ରନ୍ ବିଏ.୨ ସବଭାରିଆଣ୍ଟ ପାଇଁ ପ୍ରଭାବଶାଳୀ ଦେଖାଯାଏ ନାହିଁ ଏବଂ ଏହା ଅଧାରୁ ଅଧିକ ମାମଲା ହୋଇଥିଲେ ସୁପାରିଶ କରାଯାଏ ନାହିଁ । ^[୭] ^[୮] ^[୯] ଏହା ଏକ ଶିରାରେ ଧୀରେ ଧୀରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ଦିଆଯାଏ ।^[୧]

ଏହାର ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆନାଫାଇଲକ୍ସିସ୍ ସହିତ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ହୋଇପାରେ ।^[୧] ପ୍ରାୟ ୨,୦୦୦ ଲୋକଙ୍କ ମଧ୍ୟରୁ ଜଣକର ଆନାଫାଇଲକ୍ସିସ୍ ହୁଏ ।^[୧] ଗର୍ଭାବସ୍ଥାରେ କିମ୍ବା ସ୍ତନ୍ୟପାନରେ ସୁରକ୍ଷା ମିଳିବା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୫] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଏସଏଆରଏସ-କୋଭି-୨ର ସ୍ପାଇକ୍ ପ୍ରୋଟିନ୍ ସହିତ ସଂଲଗ୍ନ ହେବାଦ୍ୱାରା ଶରୀରର କୋଷରେ ଭୂତାଣୁ ପ୍ରବେଶ କରିବାରେ ଅସମର୍ଥ ହୁଏ ।^[୧]

୨୦୨୧ ମସିହାରେ ୟୁରୋପରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ସୋଟ୍ରୋଭିମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ୨୦୨୧ ସୁଦ୍ଧା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ଜରୁରୀକାଳୀନ ବ୍ୟବହାର ପ୍ରାଧିକରଣ (EUA) ଅଛି ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହାର ଏକ ଡୋଜ ନିମନ୍ତେ ପ୍ରାୟ ୨,୧୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୧୦]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Xevudy EPAR". European Medicines Agency (EMA). 15 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୨.୦ ^୨.୧ "Xevudy". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 18 September 2021. Retrieved 17 September 2021.
↑ "TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (Xevudy)". Therapeutic Goods Administration (TGA) (Press release). 20 August 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.
↑ "COVID-19 treatment: GlaxoSmithKline Australia Pty Ltd, sotrovimab (Xevudy)". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 23 October 2021. Retrieved 22 October 2021.
↑ ^୫.୦ ^୫.୧ ^୫.୨ "Sotrovimab injection, solution, concentrate". DailyMed. Archived from the original on 7 July 2021. Retrieved 15 June 2021.
↑ "Treatments". www.bccdc.ca (in କାନାଡିୟ ଇଂରାଜୀ). Archived from the original on 9 October 2021. Retrieved 4 January 2022.
↑ "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 6 January 2022.
↑ Kreier, Freda (23 February 2022). "Will a rising Omicron variant scramble antibody treatments?". Nature: d41586–022–00419-6. doi:10.1038/d41586-022-00419-6.
↑ "FDA updates Sotrovimab emergency use authorization". FDA. Archived from the original on 28 March 2022. Retrieved 30 March 2022.
↑ "After slow start, demand for COVID monoclonal antibodies treatment skyrockets". USA Today. 25 August 2021. Archived from the original on 18 December 2021. Retrieved 18 December 2021.

[EPAR2022-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "Xevudy EPAR". European Medicines Agency (EMA). 15 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[Xevudy_APM_summary-2] ୨.୦ ^୨.୧ "Xevudy". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 18 September 2021. Retrieved 17 September 2021.

[TGA_provisional_approval-3] "TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (Xevudy)". Therapeutic Goods Administration (TGA) (Press release). 20 August 2021. Archived from the original on 4 September 2021. Retrieved 4 September 2021.

[4] "COVID-19 treatment: GlaxoSmithKline Australia Pty Ltd, sotrovimab (Xevudy)". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 23 October 2021. Retrieved 22 October 2021.

[PI2022-5] ୫.୦ ^୫.୧ ^୫.୨ "Sotrovimab injection, solution, concentrate". DailyMed. Archived from the original on 7 July 2021. Retrieved 15 June 2021.

[6] "Treatments". www.bccdc.ca (in କାନାଡିୟ ଇଂରାଜୀ). Archived from the original on 9 October 2021. Retrieved 4 January 2022.

[NIHDec2021-7] "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 6 January 2022.

[8] Kreier, Freda (23 February 2022). "Will a rising Omicron variant scramble antibody treatments?". Nature: d41586–022–00419-6. doi:10.1038/d41586-022-00419-6.

[9] "FDA updates Sotrovimab emergency use authorization". FDA. Archived from the original on 28 March 2022. Retrieved 30 March 2022.

[Price2021-10] "After slow start, demand for COVID monoclonal antibodies treatment skyrockets". USA Today. 25 August 2021. Archived from the original on 18 December 2021. Retrieved 18 December 2021.

[୧]

[୬]

[୭]

[୮]

[୯]

[୨]

[୩]

[୪]

[୫]

[୧୦]